Yes, but this is biotech investing. CLVS has 1/8th the float of ARIA, and daily volume about 1/3rd of ARIA, so there is a simple magnification to consider.
More rationally - if that is the right word - ARIA has a product on the market with sales numbers that can be used to drive any particular discussion. CLVS has 3 drug candidates - and no product sales to confuse anyone's predictions.
Still, they got what the wanted/needed, and I wish them well !